HK1208165A1 - Drug-conjugates, conjugation methods, and uses thereof - Google Patents
Drug-conjugates, conjugation methods, and uses thereofInfo
- Publication number
- HK1208165A1 HK1208165A1 HK15108785.5A HK15108785A HK1208165A1 HK 1208165 A1 HK1208165 A1 HK 1208165A1 HK 15108785 A HK15108785 A HK 15108785A HK 1208165 A1 HK1208165 A1 HK 1208165A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conjugates
- drug
- conjugation methods
- conjugation
- methods
- Prior art date
Links
- 230000021615 conjugation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
- C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647300P | 2012-05-15 | 2012-05-15 | |
US201261648532P | 2012-05-17 | 2012-05-17 | |
US201261648406P | 2012-05-17 | 2012-05-17 | |
US201261652512P | 2012-05-29 | 2012-05-29 | |
PCT/US2013/041026 WO2013173391A1 (en) | 2012-05-15 | 2013-05-14 | Drug-conjugates, conjugation methods, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208165A1 true HK1208165A1 (en) | 2016-04-01 |
Family
ID=49584226
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108785.5A HK1208165A1 (en) | 2012-05-15 | 2015-09-09 | Drug-conjugates, conjugation methods, and uses thereof |
HK15108781.9A HK1208163A1 (en) | 2012-05-15 | 2015-09-09 | Drug-conjugates, conjugation methods, and uses thereof |
HK15108783.7A HK1208216A1 (en) | 2012-05-15 | 2015-09-09 | Drug-conjugates, conjugation methods, and uses thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108781.9A HK1208163A1 (en) | 2012-05-15 | 2015-09-09 | Drug-conjugates, conjugation methods, and uses thereof |
HK15108783.7A HK1208216A1 (en) | 2012-05-15 | 2015-09-09 | Drug-conjugates, conjugation methods, and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (6) | US9981046B2 (ja) |
EP (6) | EP2849790B1 (ja) |
JP (5) | JP6239597B2 (ja) |
CN (4) | CN104640572B (ja) |
ES (2) | ES2734259T3 (ja) |
HK (3) | HK1208165A1 (ja) |
WO (3) | WO2013173392A1 (ja) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CA2680535C (en) | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
EP2849790B1 (en) | 2012-05-15 | 2019-04-10 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
AU2013364065B2 (en) | 2012-12-21 | 2018-10-04 | Altrubio Inc. | Hydrophilic self-immolative linkers and conjugates thereof |
EP2968440B1 (en) | 2013-03-15 | 2019-06-05 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
CA2914448A1 (en) | 2013-06-12 | 2014-12-18 | Muhammad Naveed Yousaf | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof |
AU2014318826B2 (en) | 2013-09-10 | 2019-10-10 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
SG11201604879QA (en) | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
CA2921707C (en) | 2013-10-15 | 2023-03-28 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
EP3086815B1 (en) * | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
WO2015095952A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Var2csa-drug conjugates |
AU2015213106B2 (en) * | 2014-01-28 | 2019-07-25 | Tube Pharmaceuticals Gmbh | Cytotoxic tubulysin compounds for conjugation |
JP2017505777A (ja) | 2014-01-29 | 2017-02-23 | シンタ ファーマスーティカルズ コーポレーション | 標的化治療薬 |
GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
AU2015224576A1 (en) | 2014-03-03 | 2016-09-22 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
CN107041139A (zh) * | 2014-05-28 | 2017-08-11 | 艾更斯司股份有限公司 | 海兔脯氨酸‑海兔异亮氨酸肽的衍生物 |
BR112016029860A2 (pt) | 2014-06-20 | 2017-10-24 | Abgenomics Int Inc | conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos |
EA201790173A1 (ru) | 2014-07-11 | 2017-06-30 | Генмаб А/С | Антитела, связывающие axl |
SG11201701311YA (en) * | 2014-09-11 | 2017-03-30 | Seattle Genetics Inc | Targeted delivery of tertiary amine-containing drug substances |
EP4029873A1 (en) * | 2014-09-17 | 2022-07-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
KR20230158134A (ko) | 2014-10-14 | 2023-11-17 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
US20170281796A1 (en) * | 2014-12-08 | 2017-10-05 | Sorrento Therapeutics, Inc. | c-Met Antibody Drug Conjugate |
US9968683B2 (en) | 2014-12-17 | 2018-05-15 | Organolinx Corp. | Method for conjugating molecules |
EP4137159A1 (en) * | 2015-01-28 | 2023-02-22 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
EP3253212A4 (en) * | 2015-02-06 | 2018-09-19 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
CA2976050A1 (en) * | 2015-02-15 | 2016-08-18 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof |
CN106279352B (zh) * | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
JP6802840B2 (ja) | 2015-06-09 | 2020-12-23 | エックスディーシーエクスプローラー (シャンハイ) カンパニー リミテッド | 抗体薬物複合体、中間体、その製造方法、薬学的組成物及び応用 |
SI3319993T1 (sl) | 2015-07-10 | 2020-06-30 | Genmab A/S | AXL-specifični konjugati zdravila s protitelesom za zdravljenje raka |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
WO2017054080A1 (en) * | 2015-09-29 | 2017-04-06 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2017058808A1 (en) * | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
JP6486316B2 (ja) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Industrial Technology Research Institute | 抗体−薬物複合体(adc)およびそれを形成するための方法 |
CN106729743B (zh) * | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
CA3010601A1 (en) | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
UA125510C2 (uk) | 2016-03-25 | 2022-04-13 | Сіджен Інк. | Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук |
JP6858348B2 (ja) * | 2016-03-29 | 2021-04-14 | 東レ株式会社 | ペプチド誘導体及びその用途 |
WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
EP3471771A4 (en) * | 2016-05-31 | 2020-04-15 | Sorrento Therapeutics, Inc. | ANTIBODY CONJUGATES HAVING AMATOXIN DERIVATIVES AS A MEDICINAL PRODUCT |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
CN108697809A (zh) * | 2016-08-23 | 2018-10-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体-药物偶联物及其制备方法和应用 |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
JP7058666B2 (ja) * | 2016-11-25 | 2022-04-22 | マブウェル (シャンハイ) バイオサイエンス カンパニー リミテッド | 抗体-薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用 |
CN108101825B (zh) * | 2016-11-25 | 2022-02-22 | 迈威(上海)生物科技股份有限公司 | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
CA3049424A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
KR20210125094A (ko) * | 2017-04-06 | 2021-10-15 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
EP3617221A4 (en) | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
KR20200016875A (ko) | 2017-06-20 | 2020-02-17 | 마드리갈 파마슈티칼스 인코포레이티드 | 표적화 치료제 |
WO2018235024A1 (en) * | 2017-06-20 | 2018-12-27 | Sorrento Therapeutics, Inc. | CONJUGATED MEDICINE ANTI-CD38 ANTIBODY |
JP2020524156A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドMadrigal Pharmaceuticals,Inc. | 標的治療薬を含む併用療法 |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
US10799598B2 (en) | 2017-08-01 | 2020-10-13 | Sorrento Therapeutics, Inc. | Disulfide bridging conjugates |
JP7202301B2 (ja) | 2017-08-10 | 2023-01-11 | 住友ファーマ株式会社 | ヘミアスタリン誘導体及びこれらの抗体薬物複合体 |
US11389543B2 (en) | 2017-09-08 | 2022-07-19 | Seagen Inc. | Process for the preparation of tubulysins and intermediates thereof |
CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
SG11202004698RA (en) * | 2017-11-30 | 2020-06-29 | Seattle Genetics Inc | Process for the preparation of drug linker compounds |
KR20240007965A (ko) | 2017-12-06 | 2024-01-17 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
CN113683622A (zh) | 2017-12-15 | 2021-11-23 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
CN111447939B (zh) * | 2018-01-30 | 2024-07-12 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
EP3755707A1 (en) | 2018-02-20 | 2020-12-30 | Seagen Inc. | Hydrophobic auristatin f compounds and conjugates thereof |
AU2019277700A1 (en) | 2018-06-01 | 2020-11-19 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
US11998544B2 (en) | 2018-06-01 | 2024-06-04 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
US20210276971A1 (en) | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
JP2022512401A (ja) | 2018-12-13 | 2022-02-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |
KR102630499B1 (ko) | 2018-12-21 | 2024-01-30 | 어비디티 바이오사이언시스 인크. | 항트랜스페린 수용체 항체 및 이의 용도 |
SG11202106122QA (en) * | 2018-12-21 | 2021-07-29 | Seagen Inc | Adcs with thiol multiplex linkers |
CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
CN109824759A (zh) * | 2019-03-08 | 2019-05-31 | 联宁(苏州)生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
JP2022535588A (ja) | 2019-06-06 | 2022-08-09 | アビディティー バイオサイエンシーズ,インク. | 核酸ポリペプチド組成物およびその使用 |
CN114375297A (zh) | 2019-06-06 | 2022-04-19 | 艾维迪提生物科学公司 | Una亚酰胺及其用途 |
US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
WO2021144314A1 (en) | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
WO2021144313A1 (en) | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
JP2023509991A (ja) | 2020-01-13 | 2023-03-10 | シンアフィックス ビー.ブイ. | 抗体及び免疫細胞エンゲージャーのコンジュゲート |
US20230183377A1 (en) | 2020-02-26 | 2023-06-15 | Sorrento Therapeutics, Inc. | Activatable antigen binding proteins with universal masking moieties |
JP2023519169A (ja) * | 2020-03-09 | 2023-05-10 | シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | 一般的な中間体を介したドラスタチンおよびオーリスタチン類似体の効率的な調製 |
EP4121063A4 (en) | 2020-03-19 | 2024-07-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
KR20220161378A (ko) | 2020-03-27 | 2022-12-06 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
CN116096752A (zh) | 2020-06-05 | 2023-05-09 | 卫材R&D管理有限公司 | 抗bcma抗体-药物缀合物及其使用方法 |
WO2021260232A1 (en) | 2020-06-26 | 2021-12-30 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
NL2026400B1 (en) | 2020-09-02 | 2022-05-04 | Synaffix Bv | Methods for the preparation of bioconjugates |
EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
EP4213885A1 (en) | 2020-09-15 | 2023-07-26 | Synaffix B.V. | Antibody-exatecan conjugates |
NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
AR124475A1 (es) | 2020-12-23 | 2023-03-29 | Univ Muenchen Ludwig Maximilians | Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos |
EP4288108A1 (en) | 2021-02-08 | 2023-12-13 | Synaffix B.V. | Multifunctional antibodies |
CN117440832A (zh) | 2021-03-03 | 2024-01-23 | 索伦托药业有限公司 | 包括抗bcma抗体的抗体-药物缀合物 |
US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
WO2022204947A1 (zh) * | 2021-03-30 | 2022-10-06 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
EP4370555A1 (en) | 2021-07-13 | 2024-05-22 | TrueBinding, Inc. | Methods of preventing protein aggregation |
WO2023043953A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
CA3241529A1 (en) | 2021-12-23 | 2023-06-29 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024038065A1 (en) | 2022-08-15 | 2024-02-22 | Synaffix B.V. | Anthracyclins and conjugates thereof |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
EP4389152A1 (en) | 2022-12-23 | 2024-06-26 | Synaffix B.V. | Conjugates of pbd prodrugs |
CN116621927B (zh) * | 2023-01-09 | 2024-03-26 | 联宁(苏州)生物制药有限公司 | 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5780588A (en) * | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
US5525474A (en) * | 1994-01-31 | 1996-06-11 | Boehringer Mannheim Corporation | Piperidine analogs and conjugates of procainamide and NAPA |
TWI228512B (en) | 2000-10-25 | 2005-03-01 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
EP1487493B1 (en) | 2002-03-01 | 2010-01-20 | The Administrators of The Tulane Educational Fund | Conjugates of cytotoxic agents and biologically active peptides |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
EP1523493B1 (de) | 2002-07-09 | 2013-09-04 | Dömling, Alexander | Neue tubulysinanaloga |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
JP4993645B2 (ja) * | 2004-12-01 | 2012-08-08 | ジェネンテック, インコーポレイテッド | 抗体薬剤結合体および方法 |
AU2006210837B2 (en) | 2005-01-31 | 2012-07-12 | Genentech, Inc. | Anti-EphB2 antibodies and methods using same |
JP5290756B2 (ja) * | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
AR059900A1 (es) * | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
CL2007001630A1 (es) | 2006-06-06 | 2008-02-08 | Enanta Pharm Inc | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. |
EP2056709A4 (en) * | 2006-08-11 | 2013-05-01 | Univ New Jersey Med | DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE |
CN101500548A (zh) * | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
CA2680535C (en) * | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
WO2008128164A1 (en) | 2007-04-12 | 2008-10-23 | The Penn State Research Foundation | Accumulation field effect microelectronic device and process for the formation thereof |
WO2009002993A1 (en) * | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
WO2009012958A2 (en) | 2007-07-20 | 2009-01-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysin d analogues |
ES2532635T3 (es) | 2008-07-15 | 2015-03-30 | Genentech, Inc. | Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales |
NZ592255A (en) * | 2008-09-17 | 2013-07-26 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
EP2174947A1 (en) | 2008-09-25 | 2010-04-14 | Universität des Saarlandes | Bioactive pre-tubulysins and use thereof |
CA3150199A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
TWI504410B (zh) * | 2010-02-08 | 2015-10-21 | Agensys Inc | 結合至161p2f10b蛋白之抗體藥物結合物(adc) |
MX336109B (es) * | 2010-06-03 | 2016-01-08 | Genentech Inc | Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo. |
EP2579897A1 (en) * | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2409983A1 (en) * | 2010-07-19 | 2012-01-25 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Tubulysin analogues |
CN103379912B (zh) | 2010-09-29 | 2016-03-16 | 西雅图基因公司 | 正羧烷基耳他汀及其应用 |
CN103270043B (zh) | 2010-12-02 | 2015-12-16 | 内尔维阿诺医学科学有限公司 | 用于制备吗啉基蒽环衍生物的方法 |
CN103702996A (zh) * | 2011-05-27 | 2014-04-02 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
WO2012166560A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
US8815226B2 (en) * | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CA2836927A1 (en) | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
EP2849790B1 (en) | 2012-05-15 | 2019-04-10 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
SG10201702176XA (en) | 2012-06-07 | 2017-04-27 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
EP2861262B1 (en) | 2012-06-19 | 2018-11-28 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
CN104411337A (zh) | 2012-07-09 | 2015-03-11 | 基因泰克公司 | 包含抗cd79b抗体的免疫偶联物 |
SG11201604879QA (en) * | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
EP4137159A1 (en) | 2015-01-28 | 2023-02-22 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
EP3253212A4 (en) | 2015-02-06 | 2018-09-19 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
-
2013
- 2013-05-14 EP EP13790623.6A patent/EP2849790B1/en active Active
- 2013-05-14 WO PCT/US2013/041027 patent/WO2013173392A1/en active Application Filing
- 2013-05-14 CN CN201380025785.1A patent/CN104640572B/zh active Active
- 2013-05-14 EP EP19167808.5A patent/EP3590541B1/en active Active
- 2013-05-14 WO PCT/US2013/041028 patent/WO2013173393A1/en active Application Filing
- 2013-05-14 US US14/401,115 patent/US9981046B2/en active Active
- 2013-05-14 ES ES13790623T patent/ES2734259T3/es active Active
- 2013-05-14 ES ES19167808T patent/ES2887208T3/es active Active
- 2013-05-14 EP EP21189993.5A patent/EP3925627A1/en active Pending
- 2013-05-14 US US14/401,114 patent/US9884127B2/en active Active
- 2013-05-14 JP JP2015512769A patent/JP6239597B2/ja active Active
- 2013-05-14 JP JP2015512770A patent/JP6239598B2/ja active Active
- 2013-05-14 US US14/401,318 patent/US9801951B2/en active Active
- 2013-05-14 EP EP13790777.0A patent/EP2850059A4/en not_active Ceased
- 2013-05-14 WO PCT/US2013/041026 patent/WO2013173391A1/en active Application Filing
- 2013-05-14 EP EP13790334.0A patent/EP2849797B1/en active Active
- 2013-05-14 CN CN201380025775.8A patent/CN104662000B/zh active Active
- 2013-05-14 CN CN201380025774.3A patent/CN104379168B/zh active Active
- 2013-05-14 EP EP18199921.0A patent/EP3520817A1/en active Pending
- 2013-05-14 JP JP2015512771A patent/JP6280103B2/ja active Active
- 2013-05-14 CN CN201710584374.6A patent/CN107982545B/zh active Active
-
2015
- 2015-09-09 HK HK15108785.5A patent/HK1208165A1/xx unknown
- 2015-09-09 HK HK15108781.9A patent/HK1208163A1/xx unknown
- 2015-09-09 HK HK15108783.7A patent/HK1208216A1/xx unknown
-
2017
- 2017-08-17 US US15/679,599 patent/US20180085471A1/en not_active Abandoned
- 2017-11-01 JP JP2017212167A patent/JP2018052951A/ja active Pending
- 2017-11-01 JP JP2017212053A patent/JP2018058851A/ja active Pending
- 2017-12-26 US US15/854,742 patent/US10967071B2/en active Active
-
2021
- 2021-03-01 US US17/189,135 patent/US20210187119A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208163A1 (en) | Drug-conjugates, conjugation methods, and uses thereof | |
EP2877490A4 (en) | CLIENTS, CONJUGATES AND USES THEREOF | |
IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
HK1204326A1 (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor | |
EP2885318A4 (en) | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | |
HK1210913A1 (en) | Particles, methods and uses thereof | |
PL2831055T3 (pl) | Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie | |
HK1210949A1 (en) | Combinations and uses thereof | |
HK1214285A1 (zh) | 聚苯胺膜、其用途及其方法 | |
PL2650310T3 (pl) | Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania | |
EP2837627A4 (en) | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | |
GB201223330D0 (en) | Products, methods and uses | |
HK1210809A1 (en) | Beta-hexosyl-transferases and uses thereof | |
EP2836857A4 (en) | COUPLER, PROCESS AND APPLICATIONS | |
GB2517634B (en) | Connection arrangements, pivots and mechanisms | |
HK1209027A1 (en) | Vesicular formulations, uses and methods | |
EP2900693A4 (en) | ADCC-mediating antibodies, combinations and uses thereof | |
IL236027B (en) | A grenade, in particular a 40 mm grenade |